A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
Plain-language summary
This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Toripalimab (DRUG): toripalimab 240mg, d1, intravenous drip | Pegaspargase (DRUG): pegaspargase, 2000U/m2, d1, intravenous drip | Gemcitabine (DRUG): gemcitabine, 1000mg/m2, d1,d8, intravenous drip | Oxaliplatin (DRUG): oxaliplatin, 130mg/m2, d1, intravenous drip, | Definitive intensity-modulated radiotherapy (IMRT) (RADIATION): Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
- Drugs / treatments
- Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT)
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details